List of Antibodies Companies in Georgia - 8

Andson Biotech is dedicated to advancing mass spectrometry workflows by enabling simple and fast sample-to-analysis workflows. Andson's DynaChip platform leverages advanced microfluidics packaged into an easy-to-use system to make sample prep for mass spec faster (and easier) for everyone. Our platforms are designed to be flexible - they couple with any commercial MS system for on-demand mass spec analysis with no expert training required. Our focus today is on improving sample preparation and workflow integration so that everyone can get more out of their mass spec.

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Immucor is a Georgia-based healthcare technology company that develops transfusion and transplantation diagnostic equipment for hospitals and clinical laboratories.

Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases.

Lectenz Bio is developing novel products that employ our unique Lectenz® reagents and GlycoSense™ technology, to speed up and simplify the detection and discovery of disease biomarkers. These products enable targeting glycan biomarkers of clinical significance for investigation and leveraging them for advancing human health. Glycan-based biomarkers are particularly important for disease diagnosis and clinical treatment, yet their discovery and detection is challenging, due to the lack of glycan-specific reagents and tools. We are meeting this important need by developing innovative technologies in the glycosciences that will advance critical research and clinical applications. We are excited about helping to improve human health in this underexploited area. The company’s mission is to develop technologies that enable novel glycoscience applications, provide services that enhance glycan biomarker detection, and deliver tools that advance research and clinical applications.

RayBiotech is a leading life sciences company providing proteomic discovery tools to scientists in 85 countries worldwide. RayBiotech is committed to accelerating research through innovation, leadership, and excellent products and service.

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.